A number of trustees have reached the end of their period of appointment, and we are looking for three people to join our Board. The Role...

Genomics England recently hosted a roundtable event with many Cancer52 members including: Sarcoma UK, Young Lives vs Cancer, Myeloma UK,...

Cancer52 has released its latest report on health inequalities , as part of the Big Cancer52 Conversation event. >> Read report...

Fair Market Value (FMV) Guidance is now available to bring consistency to reimbursement for cross-sector partnership work. See FMV...

Cancer52 has prepared a briefing for a Westminster Hall Debate  on the ‘Potential merits of a cancer strategy for England’ . The debate...

Patient Organisation Statement on NHS England Commercial Framework Consultation

Interim CEO, Sasha Daly was pleased to meet with Minister Andrew Gwynne to talk through cancer services and how Cancer52 can work in partner

Cancer52 is delighted to announce the appointment of Chris Walden as our new CEO.

Longstanding CEO, Jane Lyons stepped down on Monday 15th July. Sasha Daly , Director for Policy at Cancer52, is Interim CEO during the...

Cancer52 has launched a manifesto called   ‘The Other Half. A manifesto to transform outcomes for people with rare and less common...